on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
RiboStruct is developing the first generic treatment for genetic diseases.
RiboStruct leverages the long-term work of Marat Yusupov and Gulnara Yusupova on the crystallographic study of the eukaryotic ribosome to develop new drugs, in particular "readthrough compounds" targeting the human ribosome for the treatment of monogenic genetic diseases when they are caused by nonsense mutations (10-15% of cases). Distinctively from gene therapies, where a specific program is needed for each disease, RiboStruct develops a pharmacological "protein repair therapy" approach, with the goal to cure multiple diseases with the same molecule by acting on a common mechanism. More than 7000 genetic diseases have been described so far, affecting altogether 300 million people worlwide.
Aminoglycosides are known to help the ribosome overcome premature stop codons to restore the synthesis of full-length proteins but their high toxicity prevents their use on the long term as needed for the treatment of monogenic diseases caused by nonsense mutations.
RiboStruct is developing non-aminoglycoside readthrough compounds using a fragment- and structure-based drug design approach relying on an exclusive know-how on the crystallographic structure determination of the whole eukaryotic ribosome in complex with ligands and on the strong biophysical capabilities of its strategic partner NovAliX (http://www.novalix-pharma.com/).
Jean-Paul Renaud created RiboStruct as a spinoff company from IGBMC (Illkirch, France) end of 2015.
He was previously cofounder and CSO Science & Technology at NovAliX (2010-2014), creator and President & CEO-CSO at AliX (2002-2008), and CNRS Research Director at IGBMC (2000-2002).
Jean-Paul holds an Engineering Diploma from ENSCP (1982) and a PhD in Organic Chemistry from UPMC (1986).
Awards :
2017 Laureate, 19th French National Innovative Startup Competition (i-LAB 2017) (for RiboStruct) 2006 Laureate, Réseau Entreprendre Alsace (for AliX) 2002 Laureate, 4th French National Innovative Startup Competition (i-LAB 2002) (for AliX) 1986 Eugène Schueller Prize
Emmanuel Savioz
Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
TOLREMO is an ETH Spin-off founded in March 2017. The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. The company’s innovative therapeutic approach specifically eradicates those cancer cells that ultimately cause drug resistance. Its science-based drug discovery and development pipeline is fueled by a unique screening platform for which a patent has been filed. TOLREMO’s vision is to use its personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.
CytoReason is a big-data analytics company specializing in immunotherapy using its proprietary Cell-Centered Model. The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy datasets. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions that extend beyond the data provided by the customer and can be translated to valuable IP. CytoReason’s technology has yielded 2 pending patents, 7 scientific collaborations and 12 peer reviewed publications
Our technology integrates different genomic and proteomic measurements with clinical data and predicts cellular immunological pathways.
The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy trials. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions. The system generates immune interaction networks that extend beyond the data provided by the customer.
CytoReason is generating valuable IP and Know-How for biotech and pharmaceutical companies, universities and research institutions throughout their basic research, drug development, and clinical trials.
Investment and Licensing (In/Out) Opportunity 1: Name
Experienced Vice President Of Business Development with a demonstrated history of working in the pharmaceuticals industry. Skilled in Medical Devices, Biotechnology, Fundraising, Biomedical Engineering, and Start-ups. Strong sales professional
Michael Sokolov
Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Company Profile
DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the production of biopharmaceuticals.
We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.
DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
ADCendo is a biotech start-up company based on a novel cancer drug, invented by the company founders. The drug is an antibody-drug conjugate (ADC), targeting cancer types that currently cannot be cured. • Unmet need: Targeted therapy against sarcomas (primary bone cancer and soft tissue tumors), glioblastomas (GBM; the most malignant brain tumors) and certain types of leukemia • Product: Antibody-drug-conjugate (ADC) against the collagen receptor uPARAP , with proven in vitro efficiency against cell lines of the cancer types mentioned, and convincing in vivo proof of concept in a model of solid cancer. For sarcomas, no efficient treatment exists if metastasis has occurred. GBM is an extremely aggressive type of cancer and is incurable. For leukemia, some sub-types can be treated but relapse is common, mortality still high and additional treatment options are strongly needed.
Actual status: • Proof of concept of receptor-specific and potent killing of sarcoma, GBM and leukemic cells has been obtained in vitro • Very high efficiency and wide window of specificity • A 100 % cure rate obtained in mice with transplanted human tumor cells, with no adverse effects observed • Priority-founding patent applications filed • Commercialization process supported by pre-seed grant from Novo Seeds, Denmark • Company ADCendo has been founded • Ideal scientific and clinical network, with founders based in university and hospital positions • Contact established with key opinion leaders • Pre-clinical and early clinical development plan in place
Swiss- Israeli based company, fuses the know how of specialists in the pahrmacology and delivery fields with the aim to bring to the market novel drugs based on cannabinoid molecules as stand alone, and synergistic combinations with proper drug delivery technologies
Over 30 years of experience in the pharmaceutical world. Also engaged in medical technologies, e.g. maintaining a distribution network for high-end ICU products in Central Europe. He recognizes the potential of combining highly specialized experts with the current trends, e.g. such as drug delivery for medicinal Cannabis.
Ralph Steidl
Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Portabiles HealthCare Technologies GmbH has been founded in Nürnberg, Germany, in Dec/2016 by an experienced Management and scientific Team: Ralph Steidl (CEO), Prof. Dr. med. Jochen Klucken (University Hospital Erlangen), Prof. Dr. Björn Eskofier (University Erlangen-Nürnberg). The team works closely together since more than seven years and holds extensive competences in the fields of movement disorders, healthcare platforms, wearable technology, machine learning, data mining, and general management.
gait analysis, wearables, Medical Device, sensors, algorithms, falls prevention,
Year Founded
2016
Financial Summary
We raised in total 645.000 € through shareholder capital, convertible loans, public funding.
For medical device development, approval in Europe and US, and for sales efforts, another 1 M € are required.
Pipeline Product 1: Name/Stage
Mobile GaitLab
Product 1: Description
Worsening of the human gait is an important symptom in many chronic diseases and reason for most of the falls of elderly. An objective analysis of a patient's gait during activities of daily living delivers valuable information about the progress of a disease, the efficacy of a therapy (or a new drug), and the patient’s individual risk of falling. Mobile GaitLab consists of motion sensors integrated into the patient's shoes (prepared orthopedic shoes). They measure the gait dynamics and provide clinical grade gait parameters to the therapist (Medical Device class IIa). Doctors thereby will be able to adjust therapy solely based upon those data. Mobile GaitLab supports clinical trials for proving the efficacy of new drugs, tele-healthcare concepts (e.g. medication adjustment in Parkinson's Disease), and at a later stage prevention of falls.
Ralph Steidl, former Managing Director of Astrum IT (a medium sized SW company) has more than 15 years of experience in Management and Sales in IT and Telecommunication Industries and a high level of expertise in Digital Health and Medical Devises Development. He led many interdisciplinary R&D projects dealing with IT-interconnection in Healthcare and clinical grade wearable technologies.
Gynotech is a developer of SMAT solutions for uro-gynecology conditions such as vaginal prolapse and urinary incontinence.
Gynotech has developed the first smart, dynamic pessary that automatically adjust its size in response to the changing intr-abdominal pressures and thus provides a much better prevention of prolapse and urinary leakages.
Chairman & CEO (D.Sc. in biochemistry and pharmacology) - Meir served for 20 years as CEO of Israeli and Canadian hi-tech companies, including CEO of two technological incubators. Earlier, he was a senior executive at ICL (Israel Chemical Ltd.) Group.
.
Lior Teitelbaum
Presentation Time and Location
on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15}
Company Profile
Home / Ambulatory monitoring platform that can easily and precisely monitor the lung function, alert the medical provider on deterioration and allow change of treatment at home before Asthma exacerbation.
Non invasive accurate monitoring of breathing
Recognition of pathologic breathing patterns
Breakthrough in Respiratory Care
• Novel respiratory disease management technology
• Enables non invasive accurate monitoring of breathing
• Precise recognition of pathologic breathing patterns
• The 4 P’s: Predictive, Personalized, Preemptive, Participatory
Mr. Lior Teitelbaum, VP Business Development at MindUP is a healthcare executive with extensive experience in Business Development, Strategy, Scouting and Licensing, Partnering, Portfolio Planning and Strategy and Strategic Alliance Management in the Medical Technology, Pharmaceutical and Biotechnology industries. Prior to joining MindUP Lior was Senior Director of Business Development at BioLineRx LTD, a biopharmaceutical development company, prior to that he served as Director of Business Development at MetaCure, a medical device company focusing on treatment of type 2 diabetes, Prior to that he served as Deal flow and Business Development Manager at Elron Electronic Industries, a technology focused investment company. Lior holds an MBA from the Recanati School of management at Tel Aviv University and an MSc. in molecular genetics from the Weizmann Institute of Science.
Responsive Web Design powered by 